A prescription for amoxicillin tablets refers to a particular oral dosage form, not every product that contains amoxicillin. U.S. product labeling describes conventional film-coated tablets containing 500 mg or 875 mg of plain amoxicillin. The same 500 mg strength also appears in capsules, while combination amoxicillin/clavulanate products have separate ingredients and labels. For someone checking an order, the complete name and dosage form are therefore as important as the number on the package.
Tablet appearance is not uniform across approved product lines. Published labels describe a white-to-slightly-yellowish oval 500 mg tablet marked GG-961, a larger scored 875 mg tablet marked GG-962, and pink capsule-shaped tablets marked AMOXIL over 500 or 875. These are traceable examples, not a universal pill-identification chart. A label can establish what a particular listed product should look like, but it cannot by itself establish that a pharmacy currently stocks that product or has dispensed it to a given patient.
This guide focuses on the tablet-specific buyer task: understanding documented product differences, interpreting NDC and packaging records, checking the medication against an existing valid prescription, and resolving mismatches with the pharmacist. It does not select a dose or recommend treatment for an infection. For the broader ordering and pharmacy process, use the U.S. amoxicillin buying guide; here the emphasis stays on the identity of the finished tablet.
The tablet category addressed here consists of oral, generally film-coated products containing amoxicillin as the only antibacterial active ingredient. Product records show conventional 500 mg and 875 mg tablets. Chewable tablets, capsules and powder for oral suspension have different product descriptions, packaging and administration considerations, so a search result that simply says “amoxicillin” is not enough to identify a finished medicine.
A particularly important distinction is between plain amoxicillin 875 mg and amoxicillin/clavulanate 875 mg/125 mg. The latter contains an additional active ingredient and is not another name for the same tablet. Neither the pharmacy catalog heading nor a similar-looking numerical strength is a reason to change a prescribed product; any uncertainty about the ingredient line belongs with the dispensing pharmacist or prescriber.
The numbers 500 mg and 875 mg state the amoxicillin content of one conventional tablet. They do not indicate which strength is appropriate for a person, the interval between doses or the length of treatment. Those matters depend on clinical evaluation and the issued prescription. A strength-specific 875 mg product guide can address that buyer query in more detail; the present catalog is about comparing the tablet form and identifying finished products across both strengths.
For 500 mg orders, a formulation check is essential because 500 mg capsules also exist. The phrase “amoxicillin 500 mg” is incomplete if the prescription or price listing is intended to identify a tablet. For 875 mg orders, verify that the listing names plain amoxicillin rather than a combination medicine. Once the complete ingredient name and dosage form are confirmed, product imprints and packaging records can help resolve which labeled item the pharmacy is describing.
The examples below are drawn from published U.S. product-label records. They illustrate how identical strengths can correspond to different physical tablets and package NDCs. They are not real-time listings of pharmacy inventory, verified seller offers or proof of ongoing commercial distribution. Dates refer specifically to a labeling revision or DailyMed update; they do not date-check an individual retailer.
The Sandoz GG-961 example uses the 100-count package NDC 0781-5060-01. Its separate 20-count package, 0781-5060-20, carries a recorded marketing end date of June 30, 2015 and is intentionally excluded as a current package example. Historical label versions differ in how they report the status of the 100-count code, so even that listed NDC should not be treated as independently confirmed current supply. The 875 mg GG-962 entry is a newer Preferred Pharmaceuticals relabeled presentation, rather than the original Sandoz stock-bottle NDC.
The USAntibiotics tablets have their own branded-looking imprints and package numbers. For these examples, May 2024 is the revision date printed in prescribing information, while the corresponding DailyMed record was updated July 7, 2026. An AMOXIL imprint in this record does not mean the pharmacy is necessarily dispensing a separately marketed, currently available branded Amoxil product.
| Labeled tablet and identifier | Physical characteristics | Example package NDC | Record date and interpretation |
|---|---|---|---|
| Amoxicillin 500 mg — Sandoz GG-961 | White to slightly yellowish; oval; unscored; GG-961 / 500; 18 mm | 0781-5060-01 — 100 tablets | Sandoz DailyMed label updated Feb 22, 2024; package documented. Historical marketing-status uncertainty; retail availability unverified. |
| Amoxicillin 875 mg — Preferred Pharmaceuticals GG-962 | White to slightly yellowish; oval; scored; GG-962 / 875; 21 mm | 68788-4152-2 — 20 tablets | Preferred relabeled DailyMed record dated July 15, 2026; not a confirmed pharmacy offer. |
| Amoxicillin 500 mg — USAntibiotics AMOXIL 500 | Pink, capsule-shaped, film-coated; AMOXIL over 500 | 81964-224-14 — 20 tablets | Prescribing information revised May 2024; DailyMed record updated July 7, 2026; marketed as amoxicillin authorized generic. |
| Amoxicillin 875 mg — USAntibiotics AMOXIL 875 | Pink, capsule-shaped, film-coated; AMOXIL over 875; scored on reverse | 81964-219-14 — 20 tablets | Prescribing information revised May 2024; DailyMed record updated July 7, 2026; no verified local stock. |
Appearance can narrow an identification question but rarely completes it. The documented GG-961 tablet measures 18 mm, whereas the GG-962 example measures 21 mm and is scored; the pink AMOXIL-marked line has a different shape and color. Those measurements belong to these specific label records and must not be extended to every generic amoxicillin tablet. A change of labeler may legitimately change the look of a product while leaving the named ingredient and labeled strength the same.
The useful comparison is the complete description: the imprint on both faces, the strength, the shape, and any scoring together with the pharmacy’s recorded product. A partially legible imprint, a pill-finder photograph or a stock image from an online seller is insufficient to verify a questionable fill. If tablets appear unfamiliar, keep the dispensed container and ask the pharmacist to trace its inventory and product record before taking an unidentified tablet.
Different appearance does not automatically prove that a product is counterfeit, just as a familiar color does not prove authenticity. The important distinction is between documented appearance and verified identity of the tablets actually dispensed. That is why the table is a reference for questions, not an instruction to authenticate a medication by sight alone.
Scoring describes a physical feature of a particular tablet. The GG-962 and AMOXIL 875 examples document a score, while GG-961 500 mg is unscored. None of those observations gives a patient independent permission to halve a tablet, assemble another strength from fragments or depart from the prescription. Whether a tablet may be split depends on the specific product and professional directions, not simply on a line engraved in the coating.
If swallowing a whole tablet is difficult, ask the pharmacist or prescriber whether the prescribed product can be used as directed or whether a newly authorized alternative form is appropriate. Liquid amoxicillin suspension may be available in several concentrations, but it is a distinct dosage form, not a self-selected replacement for the tablets discussed here. A tablet that has crumbled or been damaged in transit should also be assessed rather than treated as an acceptable substitute.
A complete National Drug Code (NDC) is associated with a particular listed drug product and package configuration. One strength may have several package NDCs because the original bottle counts differ or because a relabeler lists its own presentation. For example, Preferred Pharmaceuticals identifies the GG-962 tablet with a repackager-related NDC; that does not make Preferred the original manufacturer of the tablet. A patient’s vial may not show the original stock package code, so the pharmacist’s records are often the way to connect a fill to a listed package.
FDA approval is a separate regulatory determination. An ANDA is a pathway for approved generic drugs, whereas an authorized generic can be marketed under an approved NDA rather than its own ANDA. DailyMed publishes structured labeling, and drug listing supplies identifiers; neither a listed NDC nor a published label alone establishes FDA approval, insurance coverage or local pharmacy supply. When the approval pathway matters, it should be assessed through the relevant application record, not inferred from a code on the label.
A labeler can be the entity responsible for a marketed presentation without necessarily being the factory that manufactured the tablets. The full company-by-company distinction belongs in the U.S. generic manufacturers and labelers directory. On this tablet page, understanding those roles mainly prevents a buyer from mistaking a relabeled package or an AMOXIL imprint for proof of brand status.
The package size in a product listing describes the manufacturer or relabeler presentation. It is not necessarily the quantity a patient will receive. A pharmacy can use stock bottles to prepare a patient-specific fill, with the authorized quantity recorded on the prescription and patient label. Consequently, the 100-count Sandoz example should never be read as advice to buy 100 tablets or as a promise that this stock package will be provided.
What matters at pickup or delivery is the quantity the pharmacy actually dispensed and whether any partial-fill arrangement has been explained. If the vial count seems inconsistent with the prescription, ask the pharmacist to reconcile it. This is a question about the documented fill, not about which factory bottle happened to appear on a product information page.
Film-coated tablets may contain different binders, disintegrants, pigments and coating ingredients depending on their specific label. Color alone cannot establish the contents of that coating, and a general amoxicillin product summary may not answer a question about a particular excipient. Someone with a known sensitivity to an ingredient should ask the pharmacist to check the exact dispensed product’s ingredient listing rather than assuming all 500 mg or 875 mg tablets have identical inactive components.
A history of a serious reaction to amoxicillin, penicillins or another beta-lactam antibiotic is different from an ordinary preference for a tablet appearance and must be disclosed to the clinician and pharmacist before taking the medicine. Severe reactions can be dangerous; a patient with symptoms suggesting a serious allergic reaction needs urgent medical attention rather than a pill-imprint comparison. This page is not intended to replace a clinical allergy assessment or the separate product safety information.
A valid prescription is required for amoxicillin in the United States. During fulfillment, the pharmacy must check the order and select an appropriate dispensed product through its professional procedures. From the patient’s standpoint, the essential product match is concise: complete active-ingredient name, tablet dosage form, prescribed strength and authorized quantity, followed by an explanation of any unexpected manufacturer or imprint. The pharmacy’s dispensing record—not a generic search result—should support the identity of the tablets being supplied.
A local pharmacy can clarify the product during pickup, including any change in appearance from an earlier fill. For pickup timing or inventory confirmation, the separate local pharmacy guide addresses that service. If an order is shipped, the same questions apply: which pharmacy actually dispensed the medicine, what was recorded, and whom the patient can contact about an unexplained mismatch after delivery. Neither an online “in stock” indicator nor a label photo guarantees the final product or timing.
If the prescribed tablets cannot be supplied, ask the pharmacy to explain the options that require a prescriber’s involvement. A patient should not independently use different strengths, switch to capsules or combination amoxicillin/clavulanate, or use leftover tablets to complete a course. The choice of medicine and its directions remains a clinical matter.
A useful price comparison holds the prescription constant: plain amoxicillin tablets, the actual prescribed strength and quantity, and the relevant payment method. A quote for 500 mg capsules is not a like-for-like tablet quote merely because both include “500 mg.” Likewise, a seller advertising amoxicillin/clavulanate 875/125 mg is offering a different medicine from plain amoxicillin 875 mg. Ingredient and dosage-form mismatches can make an apparently cheaper offer irrelevant.
For a meaningful total, ask the pharmacy what the authorized fill would cost under the proposed cash, insurance or discount arrangement and whether the quote includes any additional dispensing or service charges. The transaction amount can vary by pharmacy and date, and an online estimate need not equal the checkout price. Product-specific quote interpretation belongs here; detailed cross-product cost comparisons remain on the amoxicillin pricing page.
The final patient container should carry readable instructions and a pharmacy-assigned expiration or beyond-use date, as applicable. This date can differ from a manufacturer’s original stock-bottle expiration because the pharmacy is dispensing into a different presentation. The appropriate storage conditions are those on the actual dispensed label, not a generic assumption based on the tablet’s color or coating. Ask the pharmacy about broken tablets, damaged seals or an unclear date before using the medicine.
Scenario: an online listing says only “amoxicillin 500 mg.” That description does not establish whether the offer refers to tablets or capsules. The buyer can ask the dispensing pharmacy for its exact dosage-form description before treating the price or availability as applicable to the prescription.
Scenario: a refill has changed from GG-962 to AMOXIL 875. Both patterns appear in published records, but that does not authenticate the individual fill. The pharmacist should reconcile the actual dispensed NDC, strength and ingredient with the prescription and explain the changed appearance rather than asking the patient to rely on a photograph.
Scenario: a listed NDC has an old marketing end date. A historical package record can remain useful for identification, but it should not be interpreted as a present-day shopping option. When an online seller claims to supply an old package or an unfamiliar product, the pharmacy should substantiate the source and current legal dispensing status. For broader red flags, see the product-authenticity verification guide.
Published U.S. labels describe conventional film-coated plain-amoxicillin tablets containing 500 mg or 875 mg of amoxicillin per tablet. Those are product strengths, not recommendations about which strength to take. The prescribed medicine and directions must come from an appropriate clinician.
No. They contain the same named active ingredient at the stated strength but are different finished dosage forms. Their markings, excipients and packaging can differ, so a pharmacy should verify the formulation specified in the prescription and handle any proposed change through its normal professional process.
In the cited Sandoz product records, GG-961 identifies an unscored, 18 mm oval 500 mg tablet, while GG-962 identifies a scored, 21 mm oval 875 mg tablet. These measurements apply to those product examples only. They are not a universal appearance rule for amoxicillin tablets.
No. Published USAntibiotics records show pink tablets bearing AMOXIL markings under an amoxicillin authorized-generic listing. A pill imprint does not settle the transaction’s brand status or confirm store inventory. Ask the dispensing pharmacy about its actual product and listing if the distinction matters.
The 100-count package code is documented as NDC 0781-5060-01. A separate 20-count code, 0781-5060-20, carries a June 2015 marketing end date, so it is not presented as a current package choice. These are stock-package examples, not the quantity that a patient should receive.
Not on its own. A score is a tablet characteristic; it is not an instruction to change the prescribed amount or divide a tablet. Ask the pharmacist or prescribing clinician about the specific product and prescribed directions before altering it.
An NDC helps identify a drug-listing product and, in complete form, its reported package presentation. It does not independently establish FDA approval, whether a package remains on sale, or whether a pharmacy has it in stock. The pharmacy dispensing record is needed to resolve questions about a particular filled prescription.
The original package may contain 20, 100 or more tablets, but the pharmacy dispenses the authorized prescription quantity under applicable requirements. The patient label and dispensing record show what was actually supplied. Ask the pharmacist if that amount differs from the prescription or a partial fill was made.
Keep the tablets in their labeled container and ask the dispensing pharmacist to check the actual product, strength and dispensing record before taking an unidentified tablet. Photos and informal pill finders can be useful clues, but they do not replace verification of the medicine supplied to you.